...to treat rare diseases, hired Steve Hughes as chief development officer. He was CMO of Organovo...

...Viscient seeking merger with Organovo 3D tissue developer Viscient Biosciences Inc. proposed to merge with Organovo...
...company said a combination with Organovo would afford it opportunities in other indications. Viscient said Organovo's...
...shareholders could hold up to 43% of the combined entity. Viscient CEO Keith Murphy was Organovo's...

..."FDA Approves Astellas' Xospata in FLT-3 Positive AML" ). Organovo shares surge following bioprinting collaboration Organovo...
...of 3D bioprinted stem cell-based therapeutic tissues to treatment applications for end-stage renal disease (ESKD). Organovo...
...KLA - Klotho α Jonathan Block, Associate Editor Xospata, gilteritinib (ASP2215) Astellas Pharma Inc. Chiesi Farmaceutici S.p.A. Inhibrx Inc. Iovance Biotherapeutics Inc. Organovo...

...David Price as CFO. He was CFO at Concordia International Corp. (TSX:CXR; NASDAQ:CXRX). Bioprinting company Organovo...

...aTyr Pharma Inc. (NASDAQ:LIFE). David was chief strategy officer and EVP of preclinical development at Organovo...

...Bioprinting company Organovo Holdings Inc. (NASDAQ:ONVO) said CEO Keith Murphy will resign, effective April 21. Taylor...

...$5.0 $25.2 $29.1 15% Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (A) 10/26/16 $5.2 NA $18.4 NA Organovo...

...Wapnick as CFO. She was VP of finance at Amgen Inc. (NASDAQ:AMGN). Tissue modeling company Organovo...

...Louis O'Dea CMO. O'Dea was CMO at Oxford Immunotec Global plc (NASDAQ:OXFD). Cell therapy play Organovo...